Loading...
Docoh

Black Diamond Therapeutics (BDTX)

Employees
Data from SEC filings
Employee count
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On June 7, 2022, Black Diamond Therapeutics, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format via live webcast. Proxies were solicited pursuant to the Company’s definitive proxy statement (the “Proxy Statement”) filed on April 28, 2022 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. As of April 13, 2022, the record date for the Annual Meeting, the number of shares of the Company’s common stock, $0.0001 par value per share (“Common Stock”), outstanding and entitled to vote at the Annual Meeting was 36,287,568. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 30,154,709 thus establishing a quorum for the Annual Meeting. Shares present virtually during the Annual Meeting were considered shares of Common Stock represented in person at the Annual Meeting. Each share of Common Stock was entitled to one vote with respect to matters submitted to the Company’s stockholders at the Annual Meeting.

At the Annual Meeting, the Company’s stockholders were asked to vote on the following matters, which are described in detail in the Proxy Statement: (i) to elect three Class II director nominees to the Company’s Board of Directors (the “Board”), each to serve until the Company’s 2025 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal (“Proposal No. 1”) and (ii) to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 (“Proposal No. 2”).

The voting results reported below are final.

Proposal No. 1

Ali Behbahani, M.D., Garry E. Menzel, Ph.D. and Samarth Kulkarni, Ph.D. were duly elected to the Board as Class II directors. The results of the election were as follows:

CLASS II DIRECTOR NOMINEEFORWITHHELDBROKER
NON-
VOTES
Ali Behbahani, M.D.18,224,8838,966,0282,963,798
Garry E. Menzel, Ph.D.18,573,1338,617,7782,963,798
Samarth Kulkarni, Ph.D.21,847,7765,343,1352,963,798

Proposal No. 2

The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 was ratified. The results of the ratification were as follows:

FORAGAINSTABSTAINBROKER
NON-VOTES
30,085,95213,97554,7820

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.